Loading
institutionsInstitution
Hospital del Mar / Hospital del Mar Research Institute
Barcelona's seaside university hospital, whose research institute under Joaquín Arribas leads HER2 biology and CAR-T against breast cancer.
Also called: IMIMParc de Salut Mar
Overview
Hospital del Mar and the Hospital del Mar Research Institute (formerly IMIM) form a cancer programme with Universitat Pompeu Fabra and the Universitat Autònoma de Barcelona. Joaquín Arribas, director of the institute, characterised the truncated p95HER2 receptor and developed CAR-T and T-cell engager approaches against it, and Joan Albanell's medical oncology group is a leading breast cancer trialist within the SOLTI network. The hospital runs a comprehensive cancer service including radiotherapy, hepatobiliary surgery and haematology, an early-phase unit, and population cancer epidemiology through its public health research groups.
Location
Barcelona, ES
Type
hospital · Universitat Pompeu Fabra
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#264 · 24 points (0 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Hospital Del Mar, including child institutions. 431 works · 4,125 citations · 73% open access · 11% clinical trials · 3% reviews.
Oncology works per year
992022
782023
882024
912025
752026
Most works
- Benedetto Ielpo41 works
- Edurne Arriola28 works
- Marc G. Besselink25 works
- Mohammad Abu Hilal22 works
- Bergþór Björnsson20 works
- Fernando Burdı́o20 works
- Bas Groot Koerkamp19 works
- Ugo Boggi19 works
- Patricia Sánchez‐Velázquez18 works
- Alessandro Zerbi18 works
Most cited
- HER2 biology and p95HER2 CAR-T
- Breast cancer trials (SOLTI)
- Cancer epidemiology
- Early-phase trials
Jaume Raventós i Monjo
Managing Director (Gerent)
Hospital managementHealth services
Managing Director of Hospital del Mar in Barcelona, an academic hospital with a strong cancer research institute.
Joaquín Arribas
Director, Hospital del Mar Research Institute; ICREA Professor; formerly VHIO
HER2 biologyResistance to anti-HER2 therapyT-cell bispecifics
Cancer biologist who characterised truncated HER2 (p95HER2) and develops p95HER2-targeted T-cell engagers.
Similar pages
- PersonSandra M. Swain
Shares Trastuzumab, HER2, HER2-positive breast cancer, Monoclonal antibodies.
- PersonBarbara Bradfield
Shares Trastuzumab, HER2, HER2-positive breast cancer, Monoclonal antibodies.
- TrialTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Shares Trastuzumab, Monoclonal antibodies, Colorectal cancer.
- InstitutionIstituto Oncologico Veneto IRCCS
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies, HR-positive / HER2-negative breast cancer.
- PersonCristina Saura
Shares Vall d'Hebron University Hospital / VHIO, HER2, HER2-positive breast cancer.
- PersonHelena Earl
Shares Trastuzumab, HER2, HER2-positive breast cancer.
- TrialTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies.
- InstitutionGeorgetown Lombardi Comprehensive Cancer Center
Shares Trastuzumab, HER2, HER2-positive breast cancer, Monoclonal antibodies.
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)